drugset / Trial / NCT06897358
Leniolisib for Immune Dysregulation in CVID
Phase 2
Active not recruiting
20 enrolled
Pharming Technologies B.V.
Lahey Hospital & Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.
Timeline
- Start
- 2025-02-12
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leniolisib | Small molecule | 70 mg | — |